Results 111 to 120 of about 38,526 (184)

Real-world analysis of multiple myeloma treatments in England using the Cancer Analysis System registry. [PDF]

Sci Rep
Babu EM, Fermahan S, Bowen J, Arnold K, Broe A, Lay-Flurrie S, Matsakidis P, Chetty M, Pawlyn C.   +8 more
europepmc   +1 more source

BCL-xL as a therapeutic target in cetuximab-refractory colorectal cancer. [PDF]

Cell Death Dis
Asmanidou S, Thiel J, Ekstrom TL, Schueler J, Oswald E, Metzger P, Blaumeiser AC, Boerries M, Wiebl LM, Schiffler R, Tamas R, Essmann F, Dong M, Johnsen SA, Kontermann RE, Olayioye MA.   +15 more
europepmc   +1 more source

Pulmonary light chain deposition disease secondary to Sjögren disease: a case report. [PDF]

Front Immunol
Xu X, Wang L, Zhou C, Zhang L, Zhang T, Peng M, Feng R, Shi J.   +7 more
europepmc   +1 more source

Carfilzomib-induced sinus bradycardia: A case report and literature review. [PDF]

SAGE Open Med Case Rep
Zhao X, Sun D, Xu R, Qiu Y, Zhao S, Guo C, Chang C, Zhang J.   +7 more
europepmc   +1 more source

Azidohomoalanine (AHA) Metabolic Labeling Reveals Unique Proteomic Insights into Protein Synthesis and Degradation in Response to Bortezomib Treatment. [PDF]

Proteomes
Alhourani L, Tabana Y, Anand A, Fahlman RP.   +3 more
europepmc   +1 more source

Clinical analysis of the development of Guillain-Barré syndrome during bortezomib treatment for multiple myeloma. [PDF]

Front Neurol
Li JG, Chen CL, Liu DJ, Zheng ZH, Liu SP, Wang SY, Chen XL.   +6 more
europepmc   +1 more source

Ex Vivo Treatment Response Prediction in Multiple Myeloma: Assay Formats, Clinical Correlation, and Future Directions. [PDF]

Cancers (Basel)
Oliver GR, Barnett CC, Hightower KE, Kang Y, Baljevic M.   +4 more
europepmc   +1 more source

ACY-1215 and bortezomib cooperatively disrupt NOTCH3 signaling and induce anti-tumor effects in T-ALL models. [PDF]

Biomark Res
Angi E, Ferrarini F, Lanubile A, Montenegro F, Albano M, Mazzucato S, Reggiani F, Amaro AA, Indraccolo S, Minuzzo S.   +9 more
europepmc   +1 more source

Pharmacologic Targeting of miR29b with Bortezomib and Sorafenib to Improve Decitabine Sensitivity in Patients with Acute Myeloid Leukemia: Results from a Phase 1 Dose-Escalation Trial. [PDF]

Cancers (Basel)
Handa S, Koenig K, Zhao Q, Mims AS, Vasu S, Garzon R, Haque T, Benson D, Klisovic RB, Marcucci G, Walker AR, Bhatnagar B.   +11 more
europepmc   +1 more source

Peripheral Neuropathy Associated With Proteasome Inhibitors and Immunomodulatory Drugs: A Pharmacovigilance Disproportionality Analysis Using VigiBase. [PDF]

Pharmacol Res Perspect
Braga LP, de Pádua CAM, da Costa IHF, de Miranda Drummond PL, de Souza PHC, Fonseca LB, Rodrigues MA, Malta JS, Reis AMM.   +8 more
europepmc   +1 more source